November 21, 2025 16:30 ET | Source: Olema Oncology SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”,…
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase…
HongKong, Nov. 21, 2025 (GLOBE NEWSWIRE) -- For millions struggling with thinning hair, KX-826 is fast becoming more than just…
November 11, 2025 20:40 ET | Source: Centessa Pharmaceuticals plc BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa…
BOSTON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein…
November 10, 2025 21:56 ET | Source: Vor Biopharma BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq:…
November 08, 2025 17:13 ET | Source: Intellia Therapeutics, Inc. Deep, stable and durable reductions in kallikrein observed Among 32 patients…
November 02, 2025 09:00 ET | Source: Belite Bio, Inc MHRA response is based on the Phase 3 DRAGON interim…
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company…
TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…